Zacks Rank Upgrade: Jade Biosciences, Inc. (JBIO) has received a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks Consensus Estimate for JBIO has increased by 4.5% over the past three months, reflecting analysts' growing confidence in the company's earnings potential.
Market Positioning: JBIO specializes in semiconductor products that are not produced by major players like NVIDIA, positioning it to benefit from the anticipated growth in the semiconductor market, projected to reach $971 billion by 2028.
Investment Strategy: The Zacks Rank system, which categorizes stocks based on earnings estimate revisions, suggests that JBIO's upgrade places it among the top 20% of stocks, making it a strong candidate for potential market-beating returns.
Wall Street analysts forecast JBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JBIO is 23.75 USD with a low forecast of 17.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast JBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JBIO is 23.75 USD with a low forecast of 17.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.020
Low
17.00
Averages
23.75
High
28.00
Current: 17.020
Low
17.00
Averages
23.75
High
28.00
H.C. Wainwright
H.C. Wainwright
initiated
$25
2026-01-07
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$25
AI Analysis
2026-01-07
initiated
Reason
H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm believes the company is a well positioned to become a leader in the autoimmune space. It projects risk-adjusted revenues to reach $926M by 2037 based on JADE101 in immunoglobulin A nephropathy alone.
Clear Street
Kaveri Pohlman
Buy
initiated
$25
2025-11-24
Reason
Clear Street
Kaveri Pohlman
Price Target
$25
2025-11-24
initiated
Buy
Reason
Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm has conviction in JADE101, which it sees as a potential best-in-class anti-APRIL mAb "poised to reshape the IgAN therapeutic landscape." Jade's entry into the market "is impeccably timed," the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JBIO
Unlock Now
Guggenheim
Buy
maintain
$14 -> $17
2025-11-18
Reason
Guggenheim
Price Target
$14 -> $17
2025-11-18
maintain
Buy
Reason
Guggenheim raised the firm's price target on Jade Biosciences to $17 from $14 and keeps a Buy rating on the shares. Following the company's Q3 update, the firm made "incremental positive updates" across its IgAN model following KDIGO guideline revisions ratified in September, partially offset by increased share count, the analyst tells investors.
Guggenheim
Vamil Divan
Neutral
to
Buy
upgrade
$14
2025-06-17
Reason
Guggenheim
Vamil Divan
Price Target
$14
2025-06-17
upgrade
Neutral
to
Buy
Reason
Guggenheim analyst Vamil Divan upgraded Jade Biosciences to Buy from Neutral with a $14 price target.
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
